ATE319737T1 - Peptidderivate des apolipoproteins-a1/aii - Google Patents

Peptidderivate des apolipoproteins-a1/aii

Info

Publication number
ATE319737T1
ATE319737T1 AT01930664T AT01930664T ATE319737T1 AT E319737 T1 ATE319737 T1 AT E319737T1 AT 01930664 T AT01930664 T AT 01930664T AT 01930664 T AT01930664 T AT 01930664T AT E319737 T1 ATE319737 T1 AT E319737T1
Authority
AT
Austria
Prior art keywords
apo
amphipathic helix
domain
helix peptide
peptide
Prior art date
Application number
AT01930664T
Other languages
English (en)
Inventor
Tadahiko Kohno
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE319737T1 publication Critical patent/ATE319737T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT01930664T 2000-04-21 2001-04-23 Peptidderivate des apolipoproteins-a1/aii ATE319737T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19892000P 2000-04-21 2000-04-21

Publications (1)

Publication Number Publication Date
ATE319737T1 true ATE319737T1 (de) 2006-03-15

Family

ID=22735445

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01930664T ATE319737T1 (de) 2000-04-21 2001-04-23 Peptidderivate des apolipoproteins-a1/aii

Country Status (12)

Country Link
US (1) US6743778B2 (de)
EP (1) EP1290013B1 (de)
JP (1) JP2003530870A (de)
AT (1) ATE319737T1 (de)
AU (2) AU2001257173B2 (de)
CA (1) CA2407083A1 (de)
DE (1) DE60117781T2 (de)
DK (1) DK1290013T3 (de)
ES (1) ES2260219T3 (de)
MX (1) MXPA02010324A (de)
PT (1) PT1290013E (de)
WO (1) WO2001081376A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001081377A2 (en) * 2000-04-21 2001-11-01 Amgen, Inc. Integrin/adhesion antagonists
US8116889B2 (en) * 2002-06-27 2012-02-14 Openpeak Inc. Method, system, and computer program product for managing controlled residential or non-residential environments
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7329725B1 (en) 2003-10-29 2008-02-12 Nastech Pharmaceutical Company Inc. Phage displayed Trp cage ligands
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
JP2007531513A (ja) * 2003-11-13 2007-11-08 ハンミ ファーム．インダストリー カンパニー リミテッド 薬物のキャリアとして有用なＩｇＧＦｃ断片およびその製造方法
KR20070089996A (ko) * 2004-12-06 2007-09-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 세동맥의 구조 및 기능의 개선 방법
US7704953B2 (en) * 2006-02-17 2010-04-27 Mdrna, Inc. Phage displayed cell binding peptides
WO2007103775A2 (en) * 2006-03-03 2007-09-13 Washington University In St. Louis Biomaterials having nanoscale layers and coatings
WO2007137400A1 (en) * 2006-06-01 2007-12-06 Institut De Cardiologie De Montreal Method and compound for the treatment of valvular stenosis
AU2014268255B2 (en) * 2009-02-16 2016-04-21 Cerenis Therapeutics Holding Sa Apolipoprotein a-i mimics
EP2396017B1 (de) 2009-02-16 2015-07-01 Cerenis Therapeutics Holding SA Apolipoprotein-a-i mimetika
KR20170003611A (ko) 2014-05-02 2017-01-09 세레니스 쎄라퓨틱스 홀딩 에스에이 Ｈｄｌ 요법 마커
EP4537906A3 (de) 2015-03-25 2025-08-20 The Regents of the University of Michigan Zusammensetzungen und verfahren zur abgabe von biomakromolekülwirkstoffen
BR112019001459A2 (pt) 2016-07-27 2019-05-07 Hartis-Pharma Sa combinação, composição farmacêutica, e, método de prevenção e/ou de tratamento de uma doença ou de um distúrbio.
US20240033322A1 (en) 2020-04-16 2024-02-01 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
EP4221686A2 (de) 2020-10-01 2023-08-09 Abionyx Pharma SA Zusammensetzungen mit lipidbindenden komplexen auf proteinbasis zur verwendung zur behandlung von augenerkrankungen
WO2022219413A1 (en) 2021-04-15 2022-10-20 Abionyx Pharma Sa Use of lipid binding protein-based complexes in organ preservation solutions
AU2023251245A1 (en) 2022-04-06 2024-11-14 Abionyx Pharma Sa Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
JP2025511845A (ja) 2022-04-06 2025-04-16 アビオニクス ファーマ エスエー 脂質結合タンパク質ベースの複合体を使用した、眼疾患を治療するための方法
JP2025519606A (ja) 2022-06-10 2025-06-26 アビオニクス ファーマ エスエー 脂質結合タンパク質に基づく複合体を使用して急性状態を処置するための方法
IL317448A (en) 2022-06-10 2025-02-01 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using complexes based on lipid-binding proteins
JP2026504047A (ja) 2023-01-13 2026-02-03 アビオニクス ファーマ エスエー 脂質結合タンパク質分子療法
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
NL8720442A (nl) 1986-08-18 1989-04-03 Clinical Technologies Ass Afgeefsystemen voor farmacologische agentia.
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5733731A (en) 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
SE9103701D0 (sv) 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
DE69312700T2 (de) 1992-04-14 1998-02-19 Cornell Res Foundation Inc Makromoleküle auf basis von dendritischen polymeren und verfahren zur herstellung
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
AU6059898A (en) 1996-09-05 1998-03-26 Uab Research Foundation, The Anti-atherosclerotic peptides and a transgenic mouse model of atherosclerosis
DK0934526T3 (da) 1996-10-08 2003-05-05 Bisys B V U Fremgangsmåder og midler til udvælgelse af peptider og proteiner, der har specifik affinitet til et mål
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
GB9815505D0 (en) * 1998-07-16 1998-09-16 Adprotech Plc Polypeptide derivatives
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents

Also Published As

Publication number Publication date
EP1290013A2 (de) 2003-03-12
WO2001081376A2 (en) 2001-11-01
AU2001257173B2 (en) 2005-09-22
ES2260219T3 (es) 2006-11-01
DE60117781T2 (de) 2006-11-23
CA2407083A1 (en) 2001-11-01
AU5717301A (en) 2001-11-07
DK1290013T3 (da) 2006-06-26
US6743778B2 (en) 2004-06-01
PT1290013E (pt) 2006-06-30
MXPA02010324A (es) 2003-04-25
EP1290013B1 (de) 2006-03-08
DE60117781D1 (de) 2006-05-04
JP2003530870A (ja) 2003-10-21
WO2001081376A3 (en) 2003-01-09
US20030040470A1 (en) 2003-02-27

Similar Documents

Publication Publication Date Title
DE60117781D1 (de) Peptidderivate des apolipoproteins-a1/aii
WO2001083527A3 (en) Glucagon antagonists
Atoda et al. The primary structure of coagulation factor IX/factor X-binding protein isolated from the venom of Trimeresurus flavoviridis. Homology with asialoglycoprotein receptors, proteoglycan core protein, tetranectin, and lymphocyte Fc epsilon receptor for immunoglobulin E
AU764589B2 (en) Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease
US5491130A (en) Peptide inhibitors of fibronectin and related collagen-binding proteins
EA200201121A1 (ru) Модуляторы рецепторов паратироидного гормона и родственного паратироидному гормону белка
McGavin et al. Fibronectin binding determinants of the Staphylococcus aureus fibronectin receptor
YU95203A (sh) Peptidi i njima srodni molekuli koji se vezuju za tall-1
DE60327786D1 (de) Kdr-peptide und diese enthaltende impfstoffe
WO2005051998A3 (en) Antibodies binding to a c-terminal fragment of apolipoprotein e
Himeshima et al. Amino acid sequence of a lectin from the sea cucumber, Stichopus japonicus, and its structural relationship to the C-type animal lectin family
Lycksell et al. 1H NMR studies of mouse ribonucleotide reductase: the R2 protein carboxyl-terminal tail, essential for subunit interaction, is highly flexible but becomes rigid in the presence of protein R1
US6469138B1 (en) Thrombospondin receptor binding peptides
IL175319A0 (en) Novel phosphate-binding protein, pharmaceutical compositions containing same and use thereof
WO2001083526A3 (en) Calcitonin-related molecules
JP2004505640A5 (de)
Shibata et al. Improvement of biological activity and proteolytic stability of peptides by coupling with a cyclic peptide
JPH05502046A (ja) フィブロネクチン結合タンパク質
Bánóczi et al. Synthesis of cell-penetrating conjugates of calpain activator peptides
Thurieau et al. Design and synthesis of new linear and cyclic bradykinin antagonists
DE69732583D1 (de) Verfahren zur Spaltung eines chimeren Proteins mittels eines 'processing'-Enzyms
WO1996004926A1 (en) TWO NON-CONTIGUOUS REGIONS CONTRIBUTE TO NIDOGEN BINDING TO A SINGLE EGF-LIKE MOTIF OF THE LAMININ η1 CHAIN
ATE223927T1 (de) Mu-opioidligande: agonisten und antagonisten
WO2005041882A3 (en) Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs
JPH06504260A (ja) 両親媒性ペプチド組成物及びその類似体

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1290013

Country of ref document: EP

REN Ceased due to non-payment of the annual fee